Increasing numbers of women experience pregnancy around the time of, or after, a diagnosis of breast cancer. Understanding the effect of pregnancy on survival in women with breast cancer will help in the counseling and treatment of these women.
I n the United States, approximately 247 000 women received a diagnosis of breast cancer in 2016, including 26 392 women younger than 45 years (10.7% of all cases). 1 In recent decades, maternal age at first childbirth has risen by approximately 5 years in North America, and the fertility rate among women older than 35 years has increased. 2 Given the trend of delaying motherhood, the proportion of women who develop breast cancer while pregnant (or wish to become pregnant after undergoing breast cancer treatment) is increasing. Breast cancers diagnosed during pregnancy (or up to 1 year post partum) have unfavorable clinicopathologic features, such as high tumor grade and low expression of estrogen receptor (ER) and progesterone receptor (PR), compared with breast cancers diagnosed in nonpregnant women of the same age.
3-6 However, whether or not pregnancy compromises survival remains a matter of debate. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The treatment of these women is challenging because both the health of the mother and of the fetus need to be considered. Chemotherapy is not advisable during the first trimester of pregnancy; radiotherapy and hormonal therapies are not recommended at any time during pregnancy.
17
Pregnancy that occurs more than 1 year after a diagnosis of breast cancer does not appear to affect survival. [18] [19] [20] [21] [22] It is not clear how long a woman should wait after undergoing breast cancer treatment before attempting a pregnancy. [23] [24] [25] Most women are advised to postpone pregnancy for at least 2 years after treatment. The main reason for this recommendation is a concern that gestational hormones, in particular, estrogen, might stimulate dormant micrometastases, and thereby worsen survival. 26 This study was conducted to compare the overall survival of women diagnosed with breast cancer during pregnancy or in the postpartum period, with that of women who had breast cancer but did not become pregnant.
Methods

Study Design and Data Sources
We performed a population-based, retrospective cohort study in Ontario, Canada, linking a cancer database, a natality database, and a mortality database, located at the Institute for Clinical Evaluative Sciences, Toronto (eTable 1 in the Supplement). We linked these databases using unique encoded identifiers and analyzed them at the Women's College Hospital, Toronto. The research protocol was approved by the research ethics boards of the Sunnybrook Health Sciences Centre and the Women's College Hospital in Toronto. Under Section 45 of the Personal Health Information Protection Act, the Institute for Clinical Evaluative Sciences can receive and use health information without consent for purposes of analysis and compiling statistical information about the Canadian health care system.
Study Participants
From January 1, 2003 , to December 31, 2014, we identified 96 676 patients who were residents of Ontario and had a diagnosis of breast cancer in the Ontario Cancer Registry (eTable 2 in the Supplement). We excluded 837 cases (0.9%) that were coded as nonfemale or unknown sex, or where the death date was earlier than diagnosis date. Of the remaining cases, we excluded the following: women younger than 20 years and 45 years or older at the index date of diagnosis (82 744 For each woman in the study population, we retrieved information on the following: age at diagnosis, date of diagnosis, American Joint Commission on Cancer pathologic stage at diagnosis, ER, PR, ERBB2/HER2 (OMIM 164870) status, chemotherapy (yes or no), and radiotherapy (yes or no).
Exposures and Outcomes
The exposure was any pregnancy in the period from 5 years before, until 5 years after, the index date of diagnosis of breast cancer (eTable 3 in the Supplement). For each woman, we constructed a pregnancy history for the period of 5 years before, until 5 years after, diagnosis of breast cancer (eFigure 1 in the Supplement). For women who had a live birth (or a stillbirth), we calculated the date of conception by subtracting 9 months from the date of delivery, assuming a span of 40 weeks for a full-term pregnancy. For a woman who had an abortion, the date of conception was calculated by subtracting 3 months from the date of the procedure code.
We classified women into 4 exposure groups (eFigure 2 in the Supplement). The first group, no pregnancy, was defined as women who had no conception from 5 years before, until 5 years after, the index date of their diagnosis. The second group, pregnancy before breast cancer, was defined as women who had conception from 5 years to 1 year before the index date of their diagnosis of breast cancer. The third group, pregnancy-associated breast cancer, was defined as women who had conception from 11 months before, until 21 months after, the index date of their diagnosis. The fourth group, pregnancy following breast cancer, was defined as women who had conception from 22 to 60 months after the index date of their diagnosis.
As of the end of study follow-up, we classified each woman as alive, dead from breast cancer, dead from another cause, or dead from an unknown cause. The primary outcome was 5-year overall survival. χ 2 test to compare frequency distributions for categorical variables, and a 2-tailed t test or the Wilcoxon rank sum test to compare continuous variables, where appropriate. We defined overall survival as the period from the date of diagnosis of breast cancer to the date of death from any cause. We used the Kaplan-Meier method to estimate actuarial survival by exposure group. The log-rank test was used to compare survival rates between strata. We used the Cox proportional hazards regression model to estimate the hazard ratio (HR) for overall survival, comparing women with no pregnancy with women with pregnancy before breast cancer and women with pregnancy-associated breast cancer. We performed separate Cox proportional hazards regression models for women with abortion only and for women with live birth only (or stillbirth). We performed age-adjusted and multivariable models. The multivariable models included the year of diagnosis, age at diagnosis, cancer stage at diagnosis, ER, PR, and ERBB2/HER2 status, radiotherapy, chemotherapy, and pregnancy exposure group.
We performed a time-dependent analysis for women with pregnancy following breast cancer. [27] [28] [29] In the model, pregnancy was considered as a time-dependent covariate whereby exposure status was transferred from nonexposed to exposed at the date of conception. The immortal time (from diagnosis to conception) was combined with person-years in the unexposed group (nonpregnant women). For all estimates, P ≤ .05 was considered statistically significant. All P values were 2-tailed. SAS, version 9.2 (SAS Institute Inc), was used for all statistical analyses.
Results
We identified 7553 women with invasive breast cancer who were eligible for study entry; eTable 4 in the Supplement presents the baseline characteristics of the participants. The mean age at diagnosis of breast cancer was 39.1 years (median, 40 years; range, 20-44 years). The mean follow-up time was 5.2 years (median, 5.0 years; range, 0-11.2 years). Of all women, 5832 (77.2%) had no pregnancy, 1202 (15.9%) had 1 pregnancy, 398 (5.3%) had 2 pregnancies, and 121 (1.6%) had 3 pregnancies or more from 5 years before, until 5 years after, the index date of diagnosis of breast cancer. eTable 5 in the Supplement presents details on parity; 1302 women (17.2%) had a live birth, 14 (0.2%) had a stillbirth, and 700 (9.3%) had an abortion. eFigures 3 to 9 in the Supplement show the prevalence of pregnancy, abortion, and live birth in the 7553 women in the study from 5 years before, until 5 years after, the index date of diagnosis according to different age groups. A total of 700 women (9.3%) had an abortion from 5 years prior, to 5 years after, diagnosis of breast cancer. Most abortions (94%) occurred before the diagnosis (eFigure 4 in the Supplement).
Breast Cancer Characteristics eTable 6 in the Supplement presents baseline characteristics of breast cancers according to pregnancy group. Of 7553 women, 5832 (77.2%) had no pregnancy, 1108 (14.7%) had pregnancy before breast cancer, 501 (6.6%) had pregnancyassociated breast cancer, and 112 (1.5%) had pregnancy following breast cancer. Women with pregnancy-associated breast cancer were more likely than women with no pregnancy to be diagnosed with stage II to IV breast cancer (77.8% vs 71.5%; P < .001), to have node-positive tumors (52.1% vs 47.7%; P = .02), to have ER-negative tumors (36.5% vs 23.2%; P < .001), and to have triple-negative tumors (27.3% vs 16.8%; P = .001).
Risk of Death
A total of 975 (12.9%) women had died at the end of study followup. eFigure 10 in the Supplement shows the number of women at risk of death from the time of diagnosis of breast cancer. The actuarial 5-year overall survival rate was 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy, 85.3% (95% CI, 82.8%-87.8%) for women with pregnancy before breast cancer, and 82.1% (95% CI, 78.3%-85.9%) for women with pregnancyassociated breast cancer (log-rank P = .003) (Figure) . Fewer than 6 women died in the pregnancy following breast cancer group (actual number not shown owing to privacy protection).
The age-adjusted HR of all-cause mortality for women with pregnancy-associated breast cancer (vs women with no pregnancy) was 1.18 (95% CI, 0.91-1.53; P =.20 )( Table 1) . The multivariable HR was 1.11 (95% CI 0.86-1.45; P = .41). The multivariable HR of all-cause mortality for women with pregnancyassociated breast cancer (vs women with no pregnancy) remained unchanged in models without chemotherapy (1.12; 95% CI, 0.86-1.45; P = .40), radiotherapy (1.11; 95% CI, 0.86-1.44; P = .42), or both (1.12; 0.86-1.45; P = .40) (eTables 7 to 9 in the Supplement). Table 2 presents the HR of all-cause mortality for women who had live birth or stillbirth. In these women, the ageadjusted HR for women with pregnancy-associated breast cancer (vs women with no pregnancy) was 1.42 (95% CI, 1.06-1.90; P = .02). The multivariable HR fell to 1.24 (95% CI, 0.92- 
Pregnancy Following Breast Cancer
In this model, pregnancy was incorporated as a timedependent variable. Women with pregnancy following breast cancer were considered to be unexposed from the date of diagnosis to the date of conception and exposed from the date of conception. The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%) for women who had a live birth or stillbirth 6 months or more after diagnosis of breast cancer (vs 87.5% [95% CI, 86.5%-88.4%] for women with no pregnancy) (age-adjusted HR, 0.22; 95% CI, 0.10-0.49; P < .001) (eTable 11 in the Supplement). The annual absolute mortality rate for women who had live birth or stillbirth 6 months or more after diagnosis was 0.5%.
Survival After Pregnancy-Associated Breast Cancer
Among women with pregnancy-associated breast cancer who had a live birth or stillbirth, we examined features that affect survival (eTable 12 in the Supplement). Compared with women aged 40 to 44 years, the multivariable HR for all-cause mortality was poorer for women aged 20 to 29 years (2.06; 95% CI, 0.68-6.28; P = .20) and for women aged 30 to 34 years (1.71; 95% CI, 0.61-4.83; P = .31). The multivariable HR was lower for women with ER-positive tumors vs ER-negative tumors (0.37; 95% CI, 0.04-3.37; P = .38). eFigure 11 in the Supplement shows the unadjusted Kaplan-Meier survival curves in women with pregnancy-associated breast cancer according to age groups.
Discussion
We conducted this study to determine whether pregnancy has an adverse effect on survival in women with breast cancer and found that a pregnancy simultaneous with breast cancer was not detrimental to survival. The 5-year age-adjusted HR of allcause mortality was marginally higher for women with pregnancy-associated breast cancer vs those with no pregnancy (1.18; P = .20). The age-adjusted HR did not change substantially in the multivariable model (1.11; P = .41). We demonstrated that the strong age effect observed here may explain the survival disadvantage in this group reported in the past. We also demonstrated that a pregnancy following diagnosis of breast cancer was not detrimental to survival. In particular, compared with nonpregnant women, the risk of death significantly dropped for women who delivered 6 months or more after diagnosis of breast cancer (multivariable HR, 0.25 [eTable 11 in the Supplement]). Our estimates for pregnancy-associated breast cancer are similar to those of 2 previous population-based cohort studies that adjusted their hazard models for tumor characteristics 13,14 and chemotherapy 14 but not for radiotherapy. In a European collaborative study, Amant and colleagues 14 compared 447 cases of pregnancy-associated breast cancer with 865 cases of breast cancer in women who were not pregnant. The 5-year adjusted HR of overall mortality for women with pregnancy-associated breast cancer vs those who were not pregnant was 1.19 (95% CI, 0.73-1.93; P = .51). Rodriguez and colleagues 13 using the California Cancer Registry reported a similar estimate of the adjusted HR for women with pregnancy-associated breast cancer (1.14; 95% CI, 1.00-1.29; P = .05).
Many have proposed that pregnancy may adversely affect survival in women with breast cancer when the 2 conditions occur together.
30-35 Our study questions this position. We demonstrated a strong effect of age on survival in all hazard estimates. For pregnant women vs those who were not pregnant, the unadjusted HR was 1.50, which fell to 1.18 when we adjusted for age alone. Adjusting for factors other than age did not substantially change the HR estimates. In a populationbased study of the Swedish Cancer Registry, Johansson and colleagues also reported a strong effect of age on HR estimates; in their study, unadjusted HR fell from 1.47 to an age-adjusted HR of 1.18. 12 It has been proposed that breast cancer during pregnancy has a poorer prognosis because of a delayed diagnosis leading to advanced disease at presentation, or because of a tendency for these tumors to have aggressive biology, or from a delay (or modification) in cancer treatment to avoid harm to the fetus. 36, 37 We show that the principal underlying factor for poor prognosis is early age of diagnosis of breast cancer. We identified that, among women with pregnancyassociated breast cancer, younger women had relatively poor overall survival. Compared with the nonpregnant women, the age-adjusted HR of all-cause mortality was 1.93 for women younger than 30 years, and 1.75 for women aged 30 to 34 years (eTable 12 in the Supplement). The HRs remained high in these age groups after adjusting for tumor characteristics and treatment, at 2.06 and 1.71, respectively. Amant and colleagues 14 reported similar estimates. It is well documented that young age is independently associated with poor breast cancer survival.
38-41 In our study, among women with pregnancyassociated breast cancer, the proportion with more advanced (stages II-IV) breast cancer was 87.9% for women younger than 30 years, 83.3% for women aged 30 to 34 years, and 76.1% for women aged 35 to 39 years, compared with 62.6% for women 40 years and older (P < .001). The corresponding proportions of ER-negative tumors for these age groups were 22.7%, 20.2%, 16.8%, and 10.8%, respectively (P = .02).
Women with pregnancy-associated breast cancers were more likely than nonpregnant women to have ER-negative tumors (36.5% vs 23.2%; P < .001). The age-adjusted HR for ERnegative tumors (vs ER-positive) was 3.30 (95% CI, 1.14-9.55; P = .02). The mechanism by which the hormonal milieu of pregnancy could give rise to a higher proportion of ER-negative breast cancers is unclear. Possible explanations are that pregnancy might prevent ER-positive breast cancers, pregnancy might increase the risk of ER-negative breast cancers, and pregnancy might switch an ER-positive breast cancer to ERnegative cancer.
Our finding that pregnancy 6 months after diagnosis of breast cancer is safe is consistent with results of 3 previous cohort studies. 19, 20, 42 Mueller and colleagues 19 reported an adjusted relative risk of 1.7 (95% CI, 1.2-2.6) for death for women who had a live birth within 3 months after diagnosis of breast cancer (vs no pregnancy); the relative risk dropped to 0.38 (95% CI, 0.12-1.2) for women who delivered within 7 to 9 months after diagnosis of breast cancer. In an Australian study, Ives and colleagues 42 reported an adjusted HR of 2.20 for women who had a pregnancy less than 6 months after diagnosis of breast cancer, 0.45 for women who had a pregnancy 6 to 24 months after diagnosis, and 0.48 for women who had a pregnancy more than 24 months after diagnosis, compared with nonpregnant women. In our time-dependent analysis, the age-adjusted HR of all-cause mortality was 0.22 (P < .001) for women who had live birth or stillbirth 6 months after the index date of diagnosis of breast cancer. The HR remained unchanged in the multivariable model. The apparent survival benefit in women with pregnancy following breast cancer (vs nonpregnant women) might be owing to some degree of the so-called healthy mother effect, in which women who conceive are most likely to be a self-selected group of healthy women with better prognoses.
Limitations
Our study has some limitations. The Ontario Cancer Registry has no information on the tumor size, nodal status, ER or PR status, and ERBB2/HER2 status for cases of breast cancer that were diagnosed before 2010. For women who had a live or stillbirth, the information on gestational weeks was available only for deliveries after April 2002. Gestational weeks were not available for most women who had an abortion. We calculated an approximate date of conception, which could underestimate or overestimate, the actual time of conception. Finally, we were unable to obtain information on the use of hormonal treatment (eg, tamoxifen). Despite these limitations, to our knowledge, our study is one of the largest to date on this subject. The major strength of our study was our ability to link the Ontario Cancer Registry database to other health administrative databases of Ontario. Therefore, our cohort was representative of the entire population of Ontario. Moreover, we adjusted the hazard model for both chemotherapy and radiotherapy. Furthermore, we performed a time-dependent analysis in which we calculated the survival from the date of conception, rather than the date of diagnosis.
Conclusions
Pregnancy did not adversely affect survival in women with breast cancer. The ER status is the strongest factor that discriminates between pregnancy-associated breast cancer and breast cancer in nonpregnant women. However, adjusting for the ER status did not influence the risk of death. For breast cancer survivors who wish to conceive, the risk of death is lowest if pregnancy occurs 6 months or more after diagnosis. 7.2 (6.9; 2.9-11.0) a Pregnancy included abortion, live-birth, and stillbirth. b Definitions of exposure groups: No pregnancy: no conception from 5 years prior to, until 5 years after, the index date of breast cancer diagnosis; Pregnancy before breast cancer: conception in the interval 60 months to 12 months prior to the index date of breast cancer diagnosis; Pregnancy-associated breast cancer: conception in the interval 11 months prior to, until 21 months after, the index date of breast cancer diagnosis; Pregnancy following breast cancer: conception in the interval 22 months to 60 months after the index date of breast cancer diagnosis. a This analysis excluded 376 women who only had abortion. Of the remaining 7,177 women, 5,832 had no pregnancy; 938 had pregnancy-associated breast cancer; 320 had pregnancy before breast cancer, and 87 had pregnancy following breast cancer. The final analysis included 320 women with pregnancy-associated breast cancer. b Pregnancy-associated breast cancer: conception in the interval 11 months prior to, until 21 months after, the index date of breast cancer diagnosis. c Included for the year of diagnosis, age group, tumor size, nodal status, estrogen receptor status, progesterone receptor status, ERBB2 status, chemotherapy, and radiation therapy.
